Medtronic MiniMed 670G (first hybrid closed loop)
Medtronic
What it is
The first FDA-approved commercial hybrid closed-loop system. It automatically adjusted basal insulin using Guardian Sensor 3 but still required meal boluses and calibrations, with a fixed 120 mg/dL target. It is now superseded by newer Medtronic systems, but leaving it out erases the device that opened the commercial AID era.
Editorial review: .
Most recent recorded citation date: 2022-04-12. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Time in range: Achieved ~70-72% TIR in real-world T1D cohorts (70.4% in the 123,355-user US registry, 72% in the 14,899-user EU cohort), at the international 70% target but well below the 780G ~76% anchor; corrected up from 58 since real-world data clearly exceeds that.[5]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 74 × 20 + 77 × 20 + 45 × 10 + 72 × 5 + 70 × 5 + 45 × 5 + 25 × 5 + 10 × 10 + 42 × 20 = 5470; divide by total weight 100. Unrounded weighted result: 54.7.
Achieved ~70-72% TIR in real-world T1D cohorts (70.4% in the 123,355-user US registry, 72% in the 14,899-user EU cohort), at the international 70% target but well below the 780G ~76% anchor; corrected up from 58 since real-world data clearly exceeds that.[5]
Achieved time-below-70 of ~2.2-2.4% (2.2% in the 123,355-user US cohort, 2.4% in the EU cohort), consistent low-protection of a hybrid loop without auto-correction boluses.[5]
Automated basal modulation only: users still bolused for meals, performed calibrations, and had no automated correction boluses.[3]
Achieved GMI of 7.0% in both the US (N=123,355) and EU (N=14,899) real-world T1D cohorts, tracking a few points below the TIR score as expected.[5]
Achieved ~70-72% TIR with ~2.2% time-below-70 in the 123,355-user US cohort implies moderate variability for a first-gen hybrid loop; CV not published, and frequent Auto Mode exits add swing, so scored conservatively.[5]
Temporary targets helped, but exercise still required user planning and manual carbohydrates/bolus adjustments.[3]
Fixed 120 mg/dL Auto Mode target and fewer user-tunable settings than modern AID systems.[3]
Superseded by later Medtronic systems; included here mainly for historical and evidence-lineage completeness.[4]
An older tubed pump — a bulkier body, tubing and a separate handset make it the least discreet of current systems.
AID default: 50% glucose outcomes and low-glucose protection, 40% daily experience, 10% access and cost. Freedom includes tubing, wearability, water-use limits and controller requirements. These are editorial priorities; studies and device generations differ. Check each scorecard for its evidence and limits.
Editor’s take
The 670G should not rank highly in 2026, but it absolutely belongs in the scientific map. It was the first commercial proof that a pump, CGM and onboard algorithm could run safely at home at scale. The whole modern AID category stands on this rung.
The full picture
Why it still matters
MiniMed 670G is no longer the system to recommend first, but it was the first commercial hybrid closed loop. Its Auto Mode adjusted basal insulin automatically from Guardian Sensor 3 readings, while users still announced meals and gave boluses.
The limitations are as important as the success: fixed target, calibration burden, Auto Mode exits, no automated correction boluses, and limited customization. Those limits explain why later systems such as 780G, Control-IQ, Omnipod 5 and iLet matter.
Coming soon
ETA · Superseded by MiniMed 780G and other modern AID systems
Sources
- [1]Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes · Peer-reviewed study · 2017-03-01 — Pivotal in-home MiniMed 670G hybrid closed-loop study.
- [2]Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes · Peer-reviewed study · 2019-01-08 — Pediatric study full-text results: TIR 56.2% to 65.0%, HbA1c 7.9% to 7.5%, no severe hypoglycemia or DKA during study phase (the PubMed abstract confirms the study identity but not these figures).
- [3]FDA PMA P160017/S031 MiniMed 670G System · Regulatory decision · 2018-06-21 — FDA expansion to people with T1D aged 7 years and older.
- [4]Medtronic receives FDA approval for world's first hybrid closed-loop system · Manufacturer · 2016-09-28 — Manufacturer announcement of the original FDA approval of the MiniMed 670G.
- [5]
- [6]Real-world performance of the MiniMed 670G system in Europe (N=14,899; TIR 72.0%, GMI 7.0%, TBR<70 2.4%) · Peer-reviewed study · 2021-05-27
- [7]
- [8]